Entries by Louise Mason

Mission Therapeutics Strengthens Clinical Development Team with Appointment of Dr Judit Molnar as Senior Director, Translational Medicine

CAMBRIDGE, UK – 4 September 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat mitochondrial diseases, fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Judit Molnar, MD, PhD to Senior Director of Translational Medicine with immediate effect. Judit has over ten […]

Mission Therapeutics Appoints Dr Bobby Soni to its Board of Directors

CAMBRIDGE, UK – 8 March 2018 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Bobby Soni to its Board of Directors with immediate effect. Bobby replaces Rob Woodman as the representative for IP Group […]

Mission Therapeutics Strengthens Senior Management Team with Appointment of Dr Paul Thompson, Vice President, Clinical Development

CAMBRIDGE, UK – 1 March 2018 – Today Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect. Dr Thompson has over 15 years’ experience in translational research […]

Mission Therapeutics’ Highlights Positive Parkinson’s Disease USP30 Target and Inhibitor Data at the Society for Neuroscience 2017 Annual Meeting

CAMBRIDGE, UK –15 November 2017 – Mission Therapeutics, the leading drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, fibrosis, and other diseases with high unmet medical need, is presenting two posters with new research and preclinical data from its USP30 inhibitor Parkinson’s disease programmes today at Neuroscience […]

Mission Therapeutics’ Scientists Presenting Novel Parkinson’s USP30 Target and Inhibitor Data at the Society for Neuroscience 2017 Annual Meeting

  CAMBRIDGE, UK – November 1 2017 – Mission Therapeutics, the leading drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, is presenting research and preclinical data on its USP30 inhibitor Parkinson’s disease programmes as two posters at Neuroscience 2017, the 47th Annual Meeting of the Society for […]

Mission Therapeutics Presenting at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference

Preclinical data will be presented on novel USP30 inhibitors being developed as potential therapies for Parkinson’s disease Program of research supported by grant from The Michael J. Fox Foundation for Parkinson’s Research CAMBRIDGE, UK – 30 October 2017 – Mission Therapeutics announced that its Medical Director, CNS Translational Medicine, Dr Paul Thompson will be delivering […]

Mission Therapeutics’ Scientists Highlight Significance of Deubiquitylating Enzymes (DUBs) as Key Drug Targets

Keynote Nature article reviews drug discovery opportunities in multiple disease areas of unmet need CAMBRIDGE, UK – 29 September 2017 – An article entitled “Deubiquitylating enzymes (DUBs) and drug discovery: emerging opportunities,” written by the drug discovery team at Mission Therapeutics was published online today in the scientific journal Nature Reviews Drug Discovery. The peer-reviewed […]